Key molecule for flu infection identified

May 30, 2018, Hokkaido University
Changes in body weight after IAV infection. Mice untreated with CCB died within five days after IAV infection while the group treated with CCB (diltiazem) survived and recovered their body weights, as did a common anti-flu drug oseltamivir-treated group. Credit: Fujioka Y. et al., Cell Host

After decades of research, a research team has discovered the key receptor molecule that enhances the infection of the influenza A virus, providing a novel target for anti-flu drug development.

Viral infection starts when a particle attaches to a receptor molecule on the surface of a host cell. The virus particle then hijacks cellular machinery to enter the cell and replicate itself, establishing the infection. The key receptor molecule for the influenza A virus (IAV) has remained unidentified despite decades of research.

A research team led by Professor Yusuke Ohba of Hokkaido University previously demonstrated that changes in Ca2+ concentration in host cells play an important role in IAV infections.

In the latest study published in Cell Host & Microbe, the team has discovered that the Ca2+ channel, a transmembrane protein that allows Ca2+ to move across the cell membrane, is the key receptor molecule for IAV infections. Furthermore, treating human cells with calcium channel blockers (CCBs), which are commonly used as anti-hypertension , significantly suppressed IAV infections.

In experiments using cultured human , the team found that IAV binds to the Ca2+ channel on the cell's surface to trigger an influx of Ca2+, followed by entry of the virus and . Knocking down Ca2+ channels inhibited IAV-induced Ca2+ influx and virus entry. They also revealed that sialic acid on the Ca2+ channel is crucial for the virus to bind.

Human bronchial epithelial cells cultured with (right) or without (left) a calcium channel blocker (CCB) prior to exposure to IAV. Red signals show infected and replicated IAV. Treatment with CCB significantly suppressed IAV infections. Credit: Fujioka Y. et al., Cell Host

Finally, the team tested the effect of CCB on IAV infections using mice. When they treated the animals with CCB intranasally, a significant and dose-dependent reduction in the amount of replicated viruses was observed. When the animals were treated with high amounts of IAV, administration of CCB significantly prolonged survival and allowed weight recovery of the survivors whereas the untreated group died within five days.

"There were cases when the suppressive effect of CCB on IAV infections was comparable to that of an existing anti-flu drug. We expect that the interaction between IAV and the Ca2+ channel could be a novel and important target for future drug development," says Yusuke Ohba.

Credit: Hokkaido University

Explore further: Ebola virus exploits host enzyme for efficient entry to target cells

More information: Yoichiro Fujioka et al. A Sialylated Voltage-Dependent Ca 2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian Cells, Cell Host & Microbe (2018). DOI: 10.1016/j.chom.2018.04.015

Related Stories

Ebola virus exploits host enzyme for efficient entry to target cells

February 7, 2018
Researchers have identified a key process that enables the deadly Ebola virus to infect host cells, providing a novel target for developing antiviral drugs. The Ebola virus incorporates a cellular enzyme into its virus particles, ...

Male hormones may promote infection by virus that causes Kaposi's sarcoma

September 28, 2017
Male hormones may facilitate infection with a virus that can cause a type of cancer known as Kaposi's sarcoma. This finding, published in PLOS Pathogens by Ke Lan's group of the State Key Laboratory of Virology, Wuhan University, ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.